ATL-104 is a potent mitogen for epithelial cells of the gastrointestinal tract. In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents. The effect of ATL-104 on mucositis in patients requiring high-dose melphalan or BEAM before peripheral blood SCT (PBSCT) was investigated in a randomized, placebo-controlled, doubleblind, two-part study. Patients were randomized to ATL-104 (50, 100 or 150 mg) or placebo once daily for 3 days before chemotherapy and 3 days after PBSCT. Part one of the study was a dose-escalation design; part two was a parallel group design using all three ATL-104 doses. Patients were followed up for 28 days posttreatment. Severity of signs and symptoms were assessed and used to calculate scores for standard toxicity rating scales (WHO, Western Consortium for Cancer Nursing Research (WCCNR)). Sixty-three patients were treated. Treatment with ATL-104 substantially reduced the median duration of severe oral mucositis (WHO grade 3 or 4) compared with placebo (median duration: ATL-104 groups 2 or 3 days, placebo 10.5 days). The effect of ATL-104 on the incidence of severe oral mucositis was inconclusive. Similar results were obtained using the WCCNR Scale. Adverse events (AEs) were predominantly mild or moderate in intensity. Gastrointestinal AE were most common.
Introduction
Oral mucositis is a major non-hematologic complication of cytotoxic chemotherapy and radiotherapy. It is associated with significant morbidity, pain, dysphagia, disorder of taste, and subsequent dehydration and malnutrition. 1 Severe oral mucositis may also compromise patient outcomes, either by limiting radiotherapy or chemotherapy dose intensity 2 or by increasing the risk of infection. In addition, mucositis can have a significant economic impact because of increased hospitalization, use of opioids, and the need for parenteral or enteral nutrition. 3 The incidence and severity of oral mucositis vary, but the disease is most frequent in patients receiving head and neck radiation therapy, especially if combined with chemotherapy (85-100%), 2 SCT (from 45% up to 100% if TBI is used in addition to chemotherapy) [4] [5] [6] [7] and chemotherapy for solid tumors (up to 40%). 3 The current treatment of mucositis is primarily supportive and includes appropriate oral hygiene, non-irritating diet and oral care products, topical palliative mouth rinses, topical anesthetics and the use of systemic opioid analgesics. 8 Many of these treatments have limited benefit. More recently, there has been a focus on mechanisms of mucosal injury, in particular promotion of the growth and healing of damaged epithelial tissue. One example of this approach is palifermin (Kepivance, Amgen, Cambridge, UK), a recombinant version of human keratinocyte growth factor 1. A clinical study of palifermin in patients with hematologic malignancies treated with myelotoxic therapy before hematopoietic SCT showed significant reductions in both the incidence and duration of severe (WHO grade 3 or 4) mucositis. 9 Some plant lectins have mitogenic activity and may represent an alternative strategy for promoting epithelial growth and repair. The L-form of PHA-L, a plant lectin derived from the kidney bean, Phaseolus vulgaris, has been shown to stimulate cell division and growth in the pancreas and gastrointestinal tract in experimental rat models. 10, 11 ATL-104 is a recombinant tetrameric form of PHA-L manufactured in Pichia pastoris. Phase I clinical studies in healthy male volunteers showed that ATL-104 was well tolerated with no serious adverse events (AEs) reported. Unlike palifermin, which is administered intravenously, ATL-104 is formulated as a mouthwash, simplifying administration.
We report here the results of a proof of concept, two-part phase IIa study to assess the efficacy and safety of ATL-104 in the treatment of oral mucositis in patients undergoing peripheral blood SCT (PBSCT) after conditioning chemotherapy with either high-dose melphalan or BEAM.
Methods
The study was conducted in accordance with the ethical principles laid out in the Declaration of Helsinki and according to local regulations. Approval for the study was granted by the MHRA (the Medicines and Healthcare product Regulatory Agency), the competent Authority for the United Kingdom. The protocol and each center were approved by the London Multicentre Research Ethics Committee. Each investigator was approved by the appropriate Local Research Ethics Committee. All patients provided written informed consent before enrollment.
Patients
Male and female patients aged between 18 and 65 years with myeloma or lymphoma undergoing chemotherapy, BEAM [BiCNU (carmustine for injection), etoposide, cytarabine and melphalan] or high-dose melphalan with autologous PBSCT were considered for inclusion in the study. Eligible patients were required to have good orodental hygiene and no evident mucositis at screening. Exclusion criteria included: the presence of any condition that would preclude the patient from receiving chemotherapy associated with PBSCT, platelet count o100 Â 10 9 /l and neutrophil count o1.5 Â 10 9 /l, visible oral disease, earlier participation in another study using an unlicensed product within 1 month from the start of the study.
Study design
This was a randomized, double-blind, placebo-controlled phase IIa proof of concept pilot study in two parts. The first part was a dose escalation study designed to assess the tolerability of three ATL-104 doses (50, 100 or 150 mg once daily) in three consecutive cohorts. These doses were selected on the basis of the results of non-clinical and Phase I studies. Eligible patients in each cohort were assigned to active treatment or placebo in a 3:1 ratio. Before each dose escalation, a safety review was conducted by a team that included two physicians who were independent of the conduct of the study. Following harvest of PBSCs, patients received treatment for 3 days before beginning a course of chemotherapy. For patients receiving BEAM, chemotherapy lasted for 6 days, whereas patients receiving high-dose melphalan had 1 day of treatment. PBSCT was administered 1-2 days after completion of chemotherapy, and patients then received three once-daily doses of ATL-104 on the 3 days immediately after PBSCT. ATL-104 was administered orally by mouthwash as a 15 ml dose that was swilled in the mouth for 15-30 s and then swallowed. Patients who withdrew from treatment during part one of the study were replaced to enable a full interim analysis of safety for each dose level before starting the next level of treatment.
The second part of the study was a randomized, doubleblind, placebo-controlled parallel group study to investigate the efficacy and safety of the doses of ATL-104 used in part one of the study. Eligible patients were randomized in a 1:1:1:1 ratio to placebo or to one of the three ATL-104 doses. The dosing regimen during part two of the study was identical to part one.
Efficacy and safety end points Efficacy was assessed by observation of the severity and duration of mucositis in treated patients. The extent and severity of oral mucositis were assessed using standard toxicity rating scales including the World Health Organization (WHO) 12 and Western Consortium for Cancer Nursing Research (WCCNR) 13 scales. The WHO scale consists of an oral cavity assessment incorporating the extent of mouth ulcers, erythema, pain and soreness, and an assessment of solid and liquid intake. 12 The WCCNR scale is an assessment tool that measures anatomical changes associated with oral mucositis.
13 Table 1 provides details of the information that was used to assess the grade of mucositis for each patient. Assessments included examination to assess the extent of oral ulceration and erythema, degree of pain, analgesic use, antibiotic use, the degree of alimentation possible and the use of parenteral and nasogastric feeding or fluid replacement (Table 1) . 13 The investigators who participated in this study received training in the use of these scales.
All patients in the study were followed up for up to 28 days after dose 6 or until discharge from hospital or until resolution of mucositis (WHO grade 2 or below, as assessed by the physician). Assessments of oral mucositis were performed daily from screening until the final assessment, which was performed 28 days ( ± 3 days) after the last ATL-104 dose or at withdrawal, if sooner.
Safety and tolerability was assessed by means of AE recording and clinically significant changes in vital signs, physical examinations, clinical laboratory tests and electrocardiogram recordings. AEs were assessed daily from the first dose of study medication until the final assessment on day 28. Clinical laboratory variables including hematology, biochemistry and urinalysis were measured at screening, after ATL-104 doses 1 and 6, and at the final assessment. Electrocardiograms were performed at screening, at dose 6, and at the final assessment; and vital signs were assessed at screening, pre-and post-dose 1, at dose 3, post-dose 6, daily following dose 6 and at the final assessment. A physical examination was performed at screening, after the first dose and at the final assessment.
Pharmacokinetics
Pharmacokinetic assessments of the plasma levels of ATL-104 were performed on blood samples taken before dosing on the day of the first dose and before dosing and 2 h post-dose on the day of dose 6.
Data analysis
All data from parts one and two of the study were combined for the final efficacy and safety analyses. As this was a proof of concept pilot study, no comparative statistical analyses were performed on any of the efficacy or safety end points, except for an exploration of the difference in median duration of WHO grades 3-4 mucositis using the Wilcoxon two test. Efficacy end points were summarized as medians with minimum and maximum values, and as means with s.d. The incidence of maximum severity and duration of scores were determined. In addition, the area under the curve (AUC) of the mucositis score was determined to provide an additional measure of the severity and duration of oral mucositis. The total AUC was divided by the number of assessment days to provide an 'average' per-day assessment of mucositis severity.
All efficacy analyses presented here were performed on the intention-to-treat population, comprising all patients who received at least one dose of ATL-104 who underwent at least one post-dose mucositis assessment.
Results

Patients
Sixty-six patients were screened for entry: 30 patients in part 1, including 6 patients who were replacements (n ¼ 2) or reserve replacements (n ¼ 4) for those not receiving all six doses, which was a prerequisite of the safety assessment at each cohort level. There were 36 patients recruited into part 2. The patients who withdrew in part two were not replaced. Of the total, 64 were randomized and 63 received at least one dose of study medication. Fifty-two patients completed the study according to protocol and 11 patients discontinued prematurely (Figure 1 ). Four patients were withdrawn in part one of the study. There was one death in the 100 mg ATL-104 group because of pneumonia. In part 2 of the study, seven patients discontinued: four owing to AE (one in the 50 mg ATL-104 group, one in the 150 mg ATL-104 group and two in the placebo group), two as a result of non-compliance (one in the150 mg ATL-104 group and one in the placebo group), and one lost to follow-up in the 150 mg ATL-104 group.
Patient characteristics across the four dose groups were comparable ( Table 2 ). The mean age of the cohort was 53.3 years; 73.0% were male and 27.0% female. Overall, 60.3% received high-dose melphalan chemotherapy for multiple myeloma and 39.7% received BEAM chemotherapy for lymphoma.
Mucositis assessments
Patients in the ATL-104 active treatment groups experienced a shorter duration of grades 3-4 mucositis compared with patients in the placebo group; however, a doseresponse was not observed. The lack of dose-response may have been due to the limited range of ATL-104 doses used or the small number of patients in the study. The median duration of severe mucositis was 2.0, 2.0 and 3.0 days in the three ATL-104 dose groups (50, 100 and 150 mg) compared with 10.5 days in the placebo group (Table 3 and Figure 2 ). Statistical analysis using the Wilcoxon two test showed that Efficacy of ATL-104 for the treatment of oral mucositis A Hunter et al the median duration for the combined ATL-104 groups was statistically different from that for the placebo group (Po0.001).
The incidence of WHO grades 3-4 mucositis in the placebo and active groups was placebo 40.0%; ATL-104: 50 mg: 68.8%; 100 mg: 43.8%; 150 mg: 56.3%. When the severity and duration of mucositis were assessed together using the AUC method, patients in the ATL-104 active treatment groups performed consistently better than those receiving placebo (Figure 3) . A similar pattern was seen with results calculated using the WCCNR scale (see Supplementary Figures 4 and 5) .
Pharmacokinetic analysis
There were 52 patients who provided blood samples for pharmacokinetic analysis. In each case, the levels of ATL-104 were below the lower limit of quantification Efficacy of ATL-104 for the treatment of oral mucositis A Hunter et al (LLOQ ¼ 1500 ng/ml) for all doses and at all time points assessed.
Adverse events
There were 1113 treatment-emergent AEs reported for 62 of the 63 patients in the safety population during the study, with 143 (14%) serious AEs ( Table 4 ). The majority of the AEs were mild or moderate in intensity. The number of treatment-emergent and serious AEs was similar across all treatment groups, including placebo ( Table 4) . The most common treatment-emergent AEs (346 events in 62 of the 63 patients) were gastrointestinal, primarily nausea, vomiting and diarrhea (Table 5) . Of the 1113 AEs, 165 (14.8%) were considered to be possibly or probably related to treatment. These AEs occurred at similar frequencies across all treatment groups (Table 5) . Gastrointestinal AEs were the most common treatment-related AEs, with 115 events (69.7%) in 43 patients (Table 6) . Six patients discontinued treatment because of AEs. Two patients in the 50 mg ATL-104 group and one in the placebo group developed rashes and were withdrawn. Two patients in the 150 mg ATL-104 group withdrew: one owing to pyrexia and infection and the other owing to nausea and vomiting. One patient in the 100 mg ATL-104 group died from pneumonia.
In general, there were no clinically significant changes in hematology, biochemistry or urinalysis laboratory values during the course of the study that were attributable to ATL-104 rather than the PBSCT and associated conditioning therapy. No differences between the active treatment and placebo groups were observed. Hematological AEs were reported in eight patients, including one serious AE (low platelet count in the 150 mg ATL-104 dose group), whereas 41 biochemistry-related AEs were reported in 24 patients; however, only two were considered to be related to ATL-104 (two patients with low potassium, one in the 100 mg ATL-104 group and the other in the placebo group).
There were no differences between the active dose groups and the placebo group in terms of vital signs, physical examination and electrocardiogram. Three clinically significant abnormal electrocardiograms were reported, two cases of atrial fibrillation in the 50 and 150 mg ATL-104 dose groups, and one case of atrial flutter in a patient receiving placebo.
Discussion
Overall, the results of this exploratory phase IIa study show that ATL-104, administered as a once-daily mouthwash, substantially reduced both the duration of severe (WHO grade 3 or 4) mucositis and the overall severity and duration of mucositis (assessed by calculating the average, per day, assessment of mucositis severity) compared with placebo. In addition, ATL-104 was well tolerated, with no notable increase in AEs at any dose compared with placebo.
ATL-104 treatment consistently reduced the duration of WHO grade 3 or 4 mucositis compared with placebo, irrespective of dose, with the median duration of severe mucositis: 2 days in the ATL-104 50 mg and 100 mg dose groups, and 3 days in the ATL-104 150 mg dose group, compared with 10.5 days in the placebo group. These reductions are comparable with those seen in the palifermin clinical study, where the median duration of severe mucositis was significantly reduced from 9 days in the placebo group to 3 days in the treated group (Po0.001). If confirmed, the reduction in the duration of grades 3-4 mucositis observed with ATL-104 may reduce the requirements for enteral or parenteral nutrition and the use of opioid analgesics, which could have a significant impact on the cost of managing mucositis.
Although ATL-104 reduced the duration of severe mucositis, its effect on the incidence of severe mucositis was inconclusive. Further studies with larger numbers of Efficacy of ATL-104 for the treatment of oral mucositis A Hunter et al patients will be required to fully establish the effects of ATL-104 on the duration and severity of mucositis. Confirmation of the benefits on duration and severity achieved with ATL-104 treatment was provided using the AUC assessment, which combined the incidence and duration of mucositis during treatment and follow-up to give a daily 'average' severity score. Using this measure, treatment with ATL-104 reduced the daily average score by between 18 and 25% relative to placebo, depending on the dose used. Similar results were observed when the WCCNR scales were used.
ATL-104 was well tolerated up to a dose of 150 mg per day, with the incidence of AE in the active treatment groups no Table 6 Treatment-emergent adverse event possibly or probably related to study treatment, listed by system organ class higher than that of the placebo group. Most patients experienced AE; however, the majority of these were not related to treatment with ATL-104 but were the result of PBSCT conditioning and treatment. The number of AEs considered to be attributable to treatment was low and comparable in the active treatment and placebo groups. Furthermore, there was no evidence to suggest that the AEs observed during treatment increased with ATL-104 dose. Pharmacokinetic analysis showed that plasma ATL-104 concentration remained below detectable limits in all patients tested, irrespective of the dose administered, suggesting that ATL-104 is not systemically available.
In this preliminary study, treatment with ATL-104 substantially reduced the duration of severe mucositis and was well tolerated. These findings warrant confirmation in large-scale prospective clinical trials.
